Evidence map›Paper›PMID 37872565›Full record

ArticlePediatric rheumatology online journal2023

Potential regulatory role of the Nrf2/HMGB1/TLR4/NF-κB signaling pathway in lupus nephritis.

Shi-Jie Li, Dan-Dan Ruan, Wei-Zhen Wu, Min Wu, Qiu-Yan Wu, Han-Lu Wang, Yuan-Yuan Ji, Yan-Ping Zhang, Xin-Fu Lin, Zhu-Ting Fang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Pediatric rheumatology online journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Shi-Jie Li *Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Dan-Dan Ruan *Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Wei-Zhen Wu *Xiyuan Clinical Medical College of Beijing University of Chinese Medicine, Beijing, 100029, China.
Min Wu *Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Qiu-Yan WuFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Han-Lu WangFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Yuan-Yuan JiFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Yan-Ping ZhangFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Xin-Fu LinFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Zhu-Ting FangFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Li-Sheng LiaoFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Jie-Wei LuoFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. docluo0421@aliyun.com.
Mei-Zhu GaoFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. 250531194@qq.com.
Jia-Bin WuFujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. docwu8001@aliyun.com.
Fujian Medical University · CNFujian Provincial Hospital · CNBeijing University of Chinese Medicine · CNFuzhou Second Hospital · CN

Funding

Fujian Province Medical Innovation Foundation 2021CXB001Fujian Province Medical Innovation Foundation No. 2019-CXB-4Fujian Province Natural Science Fund Project No.2021J02053Fujian Province Natural Science Fund Project No.2022J01996the Special Research Foundation of Fujian Provincial Department of Finance No. 2020-822the Special Research Foundation of Fujian Provincial Department of Finance No.2021-917
6 · The paper itself

Abstract

objectivesSystemic lupus erythematosus is an autoimmune disease that involves multiple organ systems. One of its major complications, lupus nephritis (LN), is associated with a high mortality rate, and children-onset LN have a more severe course and worse prognosis than adults. Oxidative stress and inflammatory responses are involved in LN development and pathogenesis. Thus, this study aimed to explore the role of signaling regulation of the Nrf2/HMGB1/TLR/NF-κB pathway in LN pathogenesis and unravel the expression of TLR4

methodsC57BL/6 and MRL/lpr mice were divided into four groups: control, model, vector control, and Nrf2 overexpression groups. The vector control and Nrf2 overexpression groups were injected with adenoviral vectors into the kidney in situ. Pathological changes in kidney tissues were observed by hematoxylin-eosin staining. The expression of Nrf2, HMGB1, TLR4, NF-κB, and downstream inflammatory factors in kidney samples was analyzed by quantitative polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay. The ratios of TLR4

resultsIn MRL/lpr mice, Nrf2 was downregulated while HMGB1/TLR4/NF-κB pathway proteins were upregulated. Nrf2 overexpression decreased the expression of HMGB1, TLR4, NF-κB, and its downstream inflammatory cytokines (IL-1β and TNFα). These cytokines were negatively correlated with an increase in Nrf2 content. PC and TLR4

conclusionThis study showed severe kidney injury in an LN mouse model and an increased ratio of TLR4

Indexed as

Lupus NephritisNF-E2-Related Factor 2Signal TransductionAnimalsChildCytokinesHMGB1 ProteinHumansMiceMice, Inbred C57BLMice, Inbred MRL lprNF-kappa BToll-Like Receptor 4CytokinesHMGB1 ProteinNfe2l2 protein, mouseNF-E2-Related Factor 2NF-kappa BTLR4 protein, humanToll-Like Receptor 4Autoimmune diseaseHMGB1LNNrf2TLR4 + CXCR4 + plasma cells

Identifiers

PMID37872565
PMCPMC10594751
OpenAlexW4387875126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.